A Harris Win Could Boost FTC, NIH Drug Pricing Roles Given Presumptive Candidate’s Prior Anticompetitive Crackdown, March-In Support

Vice President Kamala Harris has made reducing drug prices a key talking point as she kicks off her campaign for president, and the presumptive Democratic nominee’s prior calls for NIH to employ its march-in authority and her crackdowns on noncompetitive industry behavior signal she would give NIH and the Federal Trade Commission key roles in policing the pharmaceutical industry if elected president in November.